Documenting Mast Cell Infiltration and Leukotriene Receptor Expression in Various Tumors: Possible Clinical Application of Common Pathological Findings Concerned with Tumor Development | Chapter 5 | Current Topics in Medicine and Medical Research Vol. 13

 Since the mechanisms underlying tumour growth are unknown, it is critical to identify and treat tumours early in order to save patients with malignant tumours. Surgery, chemotherapy, and radiotherapy are the latest treatments available to patients. However, several patients are unable to be rescued by such treatments. In certain cases of a suspected benign tumour, the best course of action is to simply monitor its progress before removing it surgically if possible. Using experimental rats with random tumours, we discovered the common features of different tumour tissues and demonstrated the effect of therapeutics that target them. The light and electron microscopes were used to analyse 26 different types of human tumours (epithelial or mesenchymal origin, malignant or benign), as well as Sprague-Dawley rats with spontaneous mammary gland tumours. Toluidine blue staining and immunohistochemical staining were used to identify mast cells and leukotriene receptors. One of the leukotriene receptor antagonists was given to the rats orally. The presence of multiple mast cells and the expression of leukotriene receptors in different tumours were discovered (human tumours and rat spontaneous tumors). And the therapeutic effects of leukotriene receptor antagonist administration on rat tumours, which blocked not only tumour progression but also angiogenesis and nerve development. Early detection and treatment of malignant tumours will be a more successful way of saving patients with such tumours. Our findings indicate that allergic reactions, in which leukotriene and leukotriene receptors tend to play a key role, may be involved in the development and progression of tumours, and that controlling such reactions may be a way to slow tumour progression. Our findings could be useful in oncology clinical applications.

Author (s) Details

Masao Sugamata
Department of Pathology, Tochigi Institute of Clinical Pathology, Tochigi, Japan.

Tomomi Ihara
Department of Pathology, Tochigi Institute of Clinical Pathology, Tochigi, Japan.

Miho Sugamata
Department of Pathology, Tochigi Institute of Clinical Pathology, Tochigi, Japan.

View Book :- https://stm.bookpi.org/CTMMR-V13/article/view/736

A Critical Discussion: Possibility of the Strategic Treatment for Various Tumors Using the Leukotriene Receptor Antagonist Based on the Common Pathologic Findings that Mast Cells and Leukotrienes are Involved in the Development and Proliferation of Tumors | Chapter 2 | Current Topics in Medicine and Medical Research Vol. 13

 One of the antiallergic drugs, the leukotriene receptor antagonist, is indicated with an asthmatic therapeutic drug. We discovered that mast cells and a leukotriene receptor were frequently present in a variety of malignant and benign tumours, proving that the allergic reaction was closely linked to tumour growth and proliferation. We also tested the effectiveness of using a leukotriene receptor antagonist to treat a spontaneous rat tumour and found it to be effective. Our findings indicate that this drug has a broad impact and has less side effects, which may lead to a debate about chemotherapy for the present malignant tumour. The latest evidence and potential prospects in the oncotherapy of the leukotriene receptor antagonist are briefly summarised in this commentary. Combination treatment with leukotriene receptor antagonists alone or other medications is expected to be a potential therapy for tumours. We also hope that preventive medicine will be created to prevent benign tumours from being malignant.

Author (s) Details

Masao Sugamata
Department of Pathology, Tochigi Institute of Clinical Pathology, Japan

View Book :- https://stm.bookpi.org/CTMMR-V13/article/view/733